Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 April 2004Website:
http://www.cytokinetics.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 23:50:51 GMTDividend
Analysts recommendations
Institutional Ownership
CYTK Latest News
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian participants.
SOUTH SAN FRANCISCO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2024 it granted stock options to purchase an aggregate of 53,417 shares of common stock, 34,684 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 34,426 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to Sung H. Lee, the Company's Executive Vice President and Chief Financial Officer, whose employment commenced on May 8, 2024, as a material inducement to his employment.
SOUTH SAN FRANCISCO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 9,803,922 shares of its common stock at a price to the public of $51.00 per share. The gross proceeds to Cytokinetics from the offering, before offering expenses payable by Cytokinetics, were approximately $500 million.
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 million of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock in the offering will be sold by Cytokinetics.
Deal Provides Cytokinetics with Diversified Access to Capital as Company Advances Its Specialty Cardiology Franchise Deal Provides Cytokinetics with Diversified Access to Capital as Company Advances Its Specialty Cardiology Franchise
Cytokinetics, Incorporated (Nasdaq: CYTK) will host the CLIMB Symposium today, May 17th, 2024 at the Mission Bay Conference Center in San Francisco.
Cytokinetics (CYTK) lacks the necessary mix of factors for a potential earnings beat in its upcoming report. Be ready with the key expectations.
Cytokinetics: CEO Talks Down Buyout Prospects
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March:
Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.45 per share a year ago.
What type of business is Cytokinetics Incorporated?
Cytokinetics Inc. is a late-stage biopharmaceutical company. The company is focused on the discovery, development, and commercialization of first-in-class muscle activators as potential treatments for debilitating diseases where muscle performance is decreased and/or diminished. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and disorders. The company is developing small molecule drug candidates specifically designed to enhance muscle function and contractility. Cytokinetics, Inc. was founded in 1997, and its headquarters are located in South San Francisco, California.
What sector is Cytokinetics Incorporated in?
Cytokinetics Incorporated is in the Healthcare sector
What industry is Cytokinetics Incorporated in?
Cytokinetics Incorporated is in the Biotechnology industry
What country is Cytokinetics Incorporated from?
Cytokinetics Incorporated is headquartered in United States
When did Cytokinetics Incorporated go public?
Cytokinetics Incorporated initial public offering (IPO) was on 30 April 2004
What is Cytokinetics Incorporated website?
https://www.cytokinetics.com
Is Cytokinetics Incorporated in the S&P 500?
No, Cytokinetics Incorporated is not included in the S&P 500 index
Is Cytokinetics Incorporated in the NASDAQ 100?
No, Cytokinetics Incorporated is not included in the NASDAQ 100 index
Is Cytokinetics Incorporated in the Dow Jones?
No, Cytokinetics Incorporated is not included in the Dow Jones index
When does Cytokinetics Incorporated report earnings?
The next expected earnings date for Cytokinetics Incorporated is 02 August 2024